



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61B 18/14	A1	(11) International Publication Number: WO 00/78240 (43) International Publication Date: 28 December 2000 (28.12.2000)
(21) International Application Number: PCT/US00/16800 (22) International Filing Date: 16 June 2000 (16.06.2000) (30) Priority Data: 09/336,021 18 June 1999 (18.06.1999) US (60) Parent Application or Grant SOMNUS MEDICAL TECHNOLOGIES, INC. [/]; (). NELSON, Lionel [/]; (). EDWARDS, Stuart, D. [/]; (). YOURGENLOW, Ashoor, S. [/]; (). NELSON, Lionel [/]; (). EDWARDS, Stuart, D. [/]; (). YOURGENLOW, Ashoor, S. [/]; (). DAVIS, Paul; ().	Published	
(54) Title: SUBMUCOSAL RADIOFREQUENCY TONSILS ABLATION DEVICE (54) Titre: DISPOSITIF D'AMYGDALECTOMIE SUB-MUQUEUSE PAR RADIOFREQUENCE (57) Abstract <p>A cell necrosis apparatus includes an elongated member with a longitudinal axis. The elongated member being is configured to be positionable and maneuverable in an oral cavity. First and second energy delivery devices are positioned at a distal portion of the elongated member. Each of the first and second energy delivery devices is laterally offset from the longitudinal axis. In another embodiment, the apparatus can also include a template with a tissue penetrating introducer and a lumen. The energy delivery device is configured to be advancable from the first lumen into a tonsil intratonsil lymphoid stroma.</p> (57) Abrégé <p>Cette invention concerne un appareil de nécrose cellulaire constitué par un élément allongé avec axe longitudinal. Cet élément est conçu de manière à pouvoir être positionné et manipulé dans une cavité buccale. Un premier et un second dispositifs d'apport d'énergie sont implantés dans la partie distale de l'élément allongé. Chacun des premier et second dispositifs d'apport d'énergie est déporté latéralement par rapport à l'axe longitudinal. Selon un autre mode de réalisation, l'appareil comprend un gabarit avec un dispositif conçu pour pénétrer dans les tissus et une lumière. Le dispositif d'apport d'énergie est conçu pour avancer de la première lumière dans un stroma lymphoïde sus-amygdalien de l'amygdale.</p>		

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 December 2000 (28.12.2000)


PCT

(10) International Publication Number
WO 00/78240 A1


- (51) International Patent Classification⁷: **A61B 18/14** (71) Applicant (for all designated States except US): **SOMNUS MEDICAL TECHNOLOGIES, INC.** [US/US]; 285 North Wolfe Road, Sunnyvale, CA 94086 (US).
- (21) International Application Number: **PCT/US00/16800** (72) Inventors; and (75) Inventors/Applicants (for US only): **NELSON, Lionel** [US/US]; 27261 Black Mountain Road, Los Altos Hills, CA 94022 (US). **EDWARDS, Stuart, D.** [US/US]; 658 Westridge Drive, Portola Valley, CA 94028 (US). **YOURGENLOW, Ashoor, S.** [US/US]; 5741 Clematis Drive #2, San Jose, CA 95124 (US).
- (22) International Filing Date: **16 June 2000 (16.06.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data: 09/336,021 **18 June 1999 (18.06.1999)** **US** (74) Agent: **DAVIS, Paul**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US).
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application: **US** 09/336,021 (CON) **18 June 1999 (18.06.1999)** (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,**

[Continued on next page]

(54) Title: **SUBMUCOSAL RADIOFREQUENCY TONSILS ABLATION DEVICE**



(57) Abstract: A cell necrosis apparatus includes an elongated member with a longitudinal axis. The elongated member being is configured to be positionable and maneuverable in an oral cavity. First and second energy delivery devices are positioned at a distal portion of the elongated member. Each of the first and second energy delivery devices is laterally offset from the longitudinal axis. In another embodiment, the apparatus can also include a template with a tissue penetrating introducer and a lumen. The energy delivery device is configured to be advancable from the first lumen into a tonsil intratonsil lymphoid stroma.



WO 00/78240 A1



LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Description

5

10

15

20

25

30

35

40

45

50

55

SUBMUCOSAL RADIOFREQUENCY TONSILS ABLATION DEVICE

BACKGROUND OF THE INVENTIONField of the Invention

This invention relates to an apparatus to treat tonsils and/or pharyngeal structures, and more particularly, to an apparatus that creates cell necrosis within the intratonsil lymphoid stroma, the pharyngeal or pterygoid fat pad while substantially preserving the underlying tonsil capsule, overlying mucosa and adjacent and/or underlying pterygoid muscle, vessels and nerves.

Description of Related Art

Tonsillectomy is a procedure indicated for recurrent infection of the tonsils and surrounding tissues and/or airway obstruction caused by the tonsils. It is one of the most frequently performed operations in the western world. Post-operatively, it is also one of the most painful due to the resultant exposure of unprotected oropharyngeal nerve and surrounding muscle tissue. The healing process is a slow taking between two to three weeks for the injured tissue to become overgrown with new epithelial/mucous membrane tissue. This period is typically characterized by considerable pain, dehydration and weight loss due to difficulty in swallowing as well as occasional hemorrhaging.

Tonsillectomies and adenotonsillectomies are some of the most commonly performed surgical procedures in the United States and elsewhere, with an estimated 340,000 procedures performed in the United States each year. The major complication of tonsillectomy is post-operative hemorrhage. With refinements in the surgical techniques for tonsil removal, electrocoagulation has been used more frequently to achieve hemostasis.

While suction electrocoagulation for removal of tonsils is an effective method with minimal blood loss (c.g. blood vessels are electrocoagulated as they are encountered), the procedure has several important limitations. First is

5 the fact that coagulation causes trauma to surrounding and subjacent tissues 1 to
2 mm beyond the point of contact. This causes unwanted tissue necrosis and
may lead to late post-operative bleeding. Also, suction electrocoagulation
10 devices heretofore presented are not good dissecting instruments. Nonetheless,
5 there is a tendency to use such electrocoagulation devices to cut through
adherent tissue which leads to even greater tissue trauma. The other option is to
switch back and forth between using a suction electrocoagulation device and a
15 dissecting instrument such as a Fischer "hockey-stick" style dissector. Such
switching between instruments prolongs the surgery and the time the patient
10 must remain under anesthetic, permits additional hemorrhaging during
instrument changes, and decreases efficiency.

Another method for the removal of tonsils involves the use of bipolar
electrocoagulating forceps. With bipolar electrocoagulation, tissue damage is
limited to the tissue between the tines of the bipolar coagulator. A
25 recent study by Dr. Mario Andrea in the October, 1993 edition of
Laryngoscope, used this technique in 265 patients. The study demonstrated
its effectiveness and also negligible delayed post-operative bleeding. The
30 bipolar electrocoagulating forceps is designed principally for coagulation.
If suction is needed, which is not uncommon, another instrument must be
20 introduced into the operating field. To some degree, a bipolar coagulator
may be used as a dissecting instrument; there are many instances where
35 conventional dissection is more advantageous as dissection is not inherent
in the bipolar coagulator's design.

There is a need for an apparatus to treat the tonsil and perform a
40 25 tonsillectomy with minimal bleeding. There is a further need for an apparatus
to treat the tonsils and perform a tonsillectomy without total removal of the
tonsils. Yet a further need exists for an apparatus to perform a tonsillectomy by
ablating the intratonsil lymphoid stroma. Still a further need exists for an
45 apparatus to treat the tonsils and perform a tonsillectomy by ablating the
30 intratonsil lymphoid stroma while preserving the tonsil's underlying fibrous
capsule and overlying mucosa.

5

SUMMARY OF THE INVENTION

10

Accordingly, an object of the invention is to provide an apparatus to treat tonsils.

5

Another object of the invention is to provide an apparatus to create controlled necrosis within a tonsil, particularly the intratonsil lymphoid stroma.

15

Still another object of the invention is to provide an apparatus to create controlled necrosis within a pharyngeal structure, particularly the pharyngeal or pterygoid fat pad.

10

A further object of the invention is to provide an apparatus to create controlled necrosis of the intratonsil lymphoid stroma while substantially preserving the tonsil's underlying fibrous capsule and overlying mucosa.

20

Yet another object of the invention is to provide a method to create controlled cell necrosis of a tonsil's intratonsil lymphoid stroma.

25

15

Still another object of the invention is to provide a method to create controlled cell necrosis of the tonsil's intratonsil lymphoid stroma while substantially preserving the underlying fibrous capsule and overlying mucosa.

30

Still yet another object of the invention is to provide a method to create controlled cell necrosis of the pharyngeal or pterygoid fat while substantially preserving the adjacent and underlying muscles, nerves and vessels.

20

35

These and other objects of the invention are achieved in a cell necrosis apparatus. The apparatus includes an elongated member with a longitudinal axis. The elongated member being is configured to be position able and maneuverable in an oral cavity. First and second energy delivery devices are positioned at a distal portion of the elongated member. Each of the first and second energy delivery devices is laterally offset from the longitudinal axis.

40

25

45

In another embodiment, the tonsil treatment apparatus includes a template including a first tissue penetrating introducer with a first lumen. A first energy delivery device is at least partially position able in the first lumen.

30

The first energy delivery device is advanceable from the first lumen into a tonsil intratonsil lymphoid stroma.

50

55

5 In yet another embodiment, a method of reducing the size of the tonsil provides an elongated member coupled to a first energy delivery device with an energy delivery surface. At least a portion of the energy delivery surface is delivered into an interior of the tonsil. Cell necrosis is created in the tonsil
10 intratonsil lymphoid stroma while preserving a tonsil fibrous capsule.

BRIEF DESCRIPTION OF THE FIGURES

15 FIG. 1 is a lateral view of the oral cavity illustrating the anatomy of the oral cavity including the tonsil and pterygoid muscle and pharyngeal/pterygoid fat pad.

20 FIG. 2a is a lateral view of the oral cavity illustrating positioning of the tonsil treatment apparatus of the present invention in the oral cavity.

FIG. 2b is a perspective view illustrating positioning of the tonsil treatment apparatus and the creation of cell necrosis of the stroma of the tonsil.

25 FIG. 3 is a lateral view of the treatment apparatus shown in FIGS. 2a and 2b, illustrating the handpiece, elongated member, template and energy delivery device of one embodiment of the apparatus.

30 FIG. 4 is a straight-on perspective view of the distal end of the handpiece shown in FIG. 3 illustrating the configuration and connection of the elongated members to the handpiece.

35 FIG. 5 is closeup view of FIG. 4 illustrating one embodiment of the template and the spacing of the electrodes within the template.

40 FIG. 6 is an oblique side view of one embodiment of the invention further illustrating the spacing of the distal portion of the elongated member, template, tissue piercing stylets and electrode as well as the use of insulating material over portions of the electrode.

45 FIG. 7 is a frontal view illustrating the tissue interface surface of the template including lumens/stylet openings.

50 FIG. 8a illustrates a perspective view /schematic diagram of the cell necrosis apparatus of the present invention coupled to an energy source and a ground pad electrode and operation of the electrode in a monopolar mode.

FIG. 8b is a perspective view/schematic diagram illustrating the current flow for RF electrodes operating in a bipolar mode.

FIG. 9a is a lateral view of distal portion of the apparatus illustrating an embodiment of the apparatus of FIG. 1 that includes tissue piercing stylets.

FIG. 9b is an angled lateral view of FIG. 8b illustrating the use of tissue piercing stylets and blunt ball tip electrode to position the electrode in the intratonsil lymphoidstoma while avoiding the back capsule wall of the tonsil.

FIG. 9c is lateral view of illustrating the use of an atraumatic/compressible coating on the electrode ball tip along with a force sensor positioned at the electrode tip to provide physician feedback.

FIG. 10 depicts a block diagram of the feed back control system that can be used with the apparatus as shown in FIGS. 2 and 3.

FIG 11 depicts a block diagram of an analog amplifier, analog multiplexer and microprocessor used with the feedback control system of Figure 10.

FIG 12 depicts a block diagram of the operations performed in the feedback control system depicted in Figure 10.

DETAILED DESCRIPTION

Referring now to FIGS. 1-2, one embodiment of a cell necrosis apparatus 10 (also called tonsil treatment apparatus 10 or submucosal tonsillectomy apparatus 10) used to treat tonsil 11 delivers energy to a treatment site 13 in the tonsil such as the intratonsil lymphoid stroma 11" (or other tonsil layer or oral structure) to create an area 13' of controlled cell necrosis an/or ablation while substantially preserving or minimizing injury to a tonsilar mucosal surface 11' and tonsil fibrous capsule 11". For purposes of this disclosure, an ablation procedure shall be meant to include one or more of the following affects: thermal damage, tissue shrinkage, tissue scarring, remodeling, debulking and ablating tissue. The necrosed or ablated area 13' results in a subsequent reduction in volume of tonsil 11 particularly at or around ablated area 13'. It will be appreciated that the apparatus of the present

invention is equally applicable or can otherwise be configured to treat the lingual tonsils, soft palate, turbinates, uvula, pharyngeal structures and the like. In one embodiment apparatus 10 can be configured to treat and ablate tissue within the pharyngeal fat pad, pterygoid fat pad or other pharyngeal structure.

Cell necrosis apparatus 10 can be positioned at a treatment site 13 to deploy one or more energy delivery devices 14, also called electrodes 14. Each energy delivery device 14 may be a needle energy delivery device and each is introduced into an interior of the tonsil 11 through a surface 11' of the tonsil. Ablation apparatus 10 may be configured for atraumatic intubation with or without visualization, provide for the delivery of oxygen or anesthetics, and can be capable of suctioning blood or other secretions.

Referring now to FIGS. 2a-2b, in one embodiment, apparatus 10 is used to treat the tonsils 11. Specifically, apparatus 10 is used to ablate the intratonsil lymphoid stroma 11" while sparing or minimizing injury to the underlying tonsil capsule 11'" and overlying mucosa 11'. Apparatus 10 is positioned transorally and electrode 14 is advanced through the tonsillar mucosa 11' under local anesthesia. An adequate temperature is attained (e.g. 70 to 100° C) at the treatment site 13 and/or surrounding tissue in order to sterilize any infected portions of the tonsil within or around treatment site 13. In other embodiments, apparatus 10 can be configured to treat and ablate selected portions of the pharyngeal fat pad or pterygoid fat pad while substantially preserving and preventing injury to overlying mucosa and underlying muscle and pharyngeal arteries, veins and nerves. Various medical imaging methods known in the art including CT scan, ultrasound, endoscopy and fluoroscopy can be used with this procedure to facilitate placement of apparatus 10 in the desired pharyngeal anatomy as well as provide the physician feedback on the ablation process.

Referring now to FIGS. 2-3, treatment apparatus 10 includes an elongated member 12 with a longitudinal axis 10'. In one embodiment elongated member 12 is coupled to a handpiece or shell 15. A plurality of energy delivery devices 14 are positioned at a distal portion 16 of elongated

5 member 12. In one embodiment, energy delivery device apparatus 10 is configured to create a selectable area of cell necrosis 13' at treatment site 13.

10 Elongated member 12 can be a catheter, hypotube, guidewire or handpiece, or a combination thereof that is configured to be both positionable and maneuverable in an oral cavity such as the throat including the pharynx and the larynx. In various embodiments, elongated member 12 can be fabricated from extrudable resilient polymers such as polyethylene, formable metals such as stainless steel and shape memory metals such as nitinol. In one embodiment 15 elongated member 12 can be a 0.035" nitinol wire which may or may not be coated with an insulating polymer material over all or part of its length.

20 Elongated member can have one or more lumens 12' configured for the advancement of guidewires, catheters, hypotubes, fiberoptic viewing devices and the like as well as providing ports for providing suction/aspiration, pressure, fluid delivery, and drug delivery. In one embodiment, elongated member 12 25 can be catheter or hypotube with an advanceable corewire 12" such as a 0.035" nitinol wire that is advanced through lumen 12' to reach a target tissue site 13.

30 In various embodiments, handpiece 15 can be cylindrically shaped and fabricated from moldable plastics such as nylon, polystyrene, polycarbonate, acrylic, or a combination thereof using injection molding or other polymer processing methods known in the art. The distal end 15' of handpiece 15 can be 35 connected to the proximal end 16' of elongated member 12 using adhesive or solvent bonding, hot melt junction, shrink tubing or other plastic joining method known in the art. In various embodiments, handpiece 15 can include a slidable mechanism or actuator 15" which is mechanically coupled to elongated member 40 25 12 to laterally advance elongated member 12 within an oral cavity and/or deflect distal portions 16 of elongated member 12. In one embodiment, actuator 15" can comprise a ring that slides over handpiece 15 along a lateral slot within the handpiece. In yet other embodiments, handpiece 15 can include an electrical 45 connector 15" such as a lemo connector used to connect electrode 14 and or sensor 22 to monitoring device 23, control system 25 or a power source 26. In 30

5 various embodiments, one or more elongated members 12 can be coupled to
handpiece 15.

10 At least a majority of energy delivery devices 14 are laterally offset from
the longitudinal axis 10' by an angle 10". In one embodiment, energy delivery
5 devices 14 are offset by approximately 90 degrees. In other embodiments,
energy delivery devices are offset in the range of 0 to 90 degrees with specific
embodiments of 15, 30, 45 and 60 degrees. The offset is preferred in order to
15 more readily position energy delivery devices 14 at an exterior 11' of an oral
anatomical structure such as tonsil 11.

10 Referring now to FIGS. 4-7, embodiments of apparatus 10 can also
include a template 17 which is positioned at the distal portion 16 of elongated
20 member 12. In one embodiment, template 17 can be a pressure plate that is
positioned on an exterior surface of the selected anatomical structure. Template
17 includes a tissue interface surface 18 (illustrated in FIG. 7) which can include
25 all of a portion of template 17 depending on the amount of contact between the
anatomical structure surface and tissue interface surface 18 (this may be
dependent on the amount of force applied to the surface of the anatomical
30 structure). In one embodiment, tissue interface surface 18 can be configured to
be tissue piercing, with a pointed and/or needle shape tip 18' similar to a
20 hypodermic needle.

35 Template 17 and also be made non-conductive to the transmission of
electrical, thermal or other electromagnetic energy. In various embodiments
template 17, can be made out of moldable thermoset plastics or forged or
machined metals such as stainless steel (304v) or tool steel. In a preferred
40 25 embodiment shown in FIG. 5, template has two stylets 24 separated by 10 mm
(at their center lines) configured to receive and guide two RF electrodes
including needle electrodes. In this embodiment, each electrode can be coupled
to a separate elongated member 12.

45 Referring to FIGS. 6 and 7, in one embodiment, template 17 can have a
30 flat lonzenged shape, while in other embodiments template 17 can be
substantially oval, circular or rectangular in shape. Also in various
50

embodiments, template 17 can be configured to have one or more lumens 24 or stylets 24 to hold/guide one or more electrodes 14 into a tonsil tissue site 13. Template 17 can be the size of a tonsil's face, while stylets 24 may be 4 mm hollow channels (or lumens 24) with needle sharp tips 24' which are capable of penetrating mucosal tissue and subjacent fibrous stroma or other tissue.

In one embodiment template 17 includes one or more electrode stylets 24 which extend from tissue interface surface 18. Stylets 24 have tissue-piercing distal ends 24'. The distal ends 14" of electrodes 14 are less tissue piercing than the distal ends 24' of stylets 24 but have geometries that are readily advanceable through tonsil tissue 11 including the intratonsil lymphoid stroma 11" as well as pharyngeal structures such as the pharyngeal or pterygoid fat pad. In other embodiments electrode tips 14" are sufficiently tissue piercing to be positioned in tonsil tissue 11 without the use of stylets 24.

In various embodiments, energy delivery device 14 can be an RF electrode, a microwave antenna, ultrasound transducer, resistive heater or liquid thermal jet. Referring now to FIGS. 8a and 8b, in a preferred embodiment, energy delivery device 14 is an RF electrode operated in either a bipolar or monopolar mode and energy source 26 is an RF source 26. In a monopolar mode of delivering RF energy, a single electrode 14 is used in combination with an indifferent electrode patch 19 electrically coupled to power source 26 that is applied to the body to form the other contact and complete an electrical circuit with power source 26. Bipolar operation is possible when two or more electrodes 14 are used. Current flows from portions of a first electrode 14 to a second electrode 14'. In a preferred embodiment, multiple RF electrodes 14 are included.

RF electrodes 14 are preferably needle electrodes with diameters in the range of 0.005 to 0.5" with specific embodiments of 0.01, 0.05 and 0.1 inches; and including needle gauges of 10-22 with specific embodiments of 12, 18 and 22 gauge. RF electrodes 14 are tissue piercing and advanceable through the selected anatomical structure. Referring back to FIG. 6, an insulator 20 can be positioned at the exterior of one or all of RF electrodes 14. Insulator 20 can be

5 a moveable sleeve, adjustable in length and in a surrounding relationship to an exterior surface of energy delivery device 14. Insulator 20 serves as a barrier to thermal or RF energy flow. Insulator 20 can be in the form of a sleeve that may be adjustably positioned at the exterior of energy delivery device 14. In various
10 5 embodiments, insulator 20 can be made of a polyester shrink wrap (0.002 inch thickness), or a polyamide, polyimide or Teflon® material.

Referring to FIGS. 6 and 7a, one or more sensors 22 can be included and positioned at a distal end 14" of electrode 14, at a distal end of insulator 20, as well as at other positions of cell necrosis apparatus 10. Sensor 22 is of
15 10 conventional design, including but not limited to thermistors, thermocouples, resistive wires, and the like. A suitable sensor 22 is a T type thermocouple with copper constantene, J type, E type, K type, fiber optics, resistive wires, thermocouple IR detectors, and the like.

Each electrode 14 can experience a steep temperature rise or gradient as
25 15 current moves outward through the electrode. This temperature rise causes tissue that is immediately adjacent to electrode 14 to reach temperatures of 100° C or more while tissue only 5 to 10 mm away may be at or near body temperature. Because of this temperature gradient, it is often necessary to place and remove electrode 14 several times from the treatment site 13 or use a
30 20 plurality of electrodes 14 to create a cell necrosis zone 13' of the desired volume. Because of significant heating of tissue immediately proximal of electrode 14, desiccation of tissue adjacent to electrode 14 may result. When the fluid within the tissue is desiccated, minimal or no electrical current flows through the tissue and heating ceases. This problem can be alleviated by using a
35 25 lower rate of heating which requires extended treatment periods. Referring now to FIG. 8a, in other embodiments the problem can be solved by coupling a cooling means or cooling device 33' to one or more electrodes 14 and/or treatment site 13. In various embodiments cooling device or means 33' can be a cooling fluid (e.g. chilled saline), a cryogenic fluid (e.g. a refrigerant) or a peltier effect device. In one embodiment cooling fluid 33 can be coupled to a fluid
40 30 delivery device 33' (e.g. a peristaltic or other pump) to facilitate delivery of

5 cooling fluid 33 to electrode 14 and/or tissue site 13. Fluid delivery device 33' may have an integral fluid reservoir 33".

Referring now to FIGS. 9a-9c, in various embodiments electrodes 14
10 may have non-conducting blunt ball tips 14" (also called atraumatic tip 14" or
5 blunt tip 14" or tip 14") which are deployed through stylets 24 into the tonsil
lymphoid stroma. In related embodiment, atraumatic tip 14" can have other
atraumatic/non piercing geometric shapes including but not limited to
15 cylindrical, circular, oval, spherical and hemispherical; one more of which may
have a concave or convex surface 14". Also blunt tip 14" can have a cross
10 sectional diameter 27 less than a cross sectional diameter 27' of an elongated
proximal portion 29 of electrode 14. Limited pressure is applied by the
20 physician to elongated member 12 to bring tip 14" of electrodes 14 into contact
with the back capsule wall of the tonsil with minimal or no penetration of the
back capsule wall. This configuration provides a more complete exposure of
25 the stromal tissue to RF energy exposure while minimizing injury and damage
to the back wall of the tonsil and/or the underlying tissue. In one embodiment
tip 14" can be coupled to a force/pressure sensor 22' coupled to a monitoring
30 device 23 to provide the physician feedback on the amount of force/pressure
being applied by tip 14" against adjacent tissue and assist him or her in reducing
20 the likelihood of penetration of the back capsule wall. In various embodiments,
force/pressure sensor 22' can include a strain gauge, or solid state based (e.g.
35 silicon) pressure/force sensor known in the art. In related embodiments
electrodes 14 can be positioned at treatment site 13 in the tonsil 11 or other oral
structure without the use of template 17. This can be achieved using electrodes
40 14 that are either tissue piercing or have fully or partially blunt tip 14". In
related embodiments, placement of electrodes 14 without template 17 can be
facilitated with the use of sensor 22 including a pressure sensor 22' positioned at
45 tip 14". Placement of electrode 14 can also be facilitated by the use of an
endoscopic or fiberoptic viewing device or a medical imaging modality known
30 in the art such as ultrasound, fluoroscopy, MRI or CT scans.

5 In various embodiments, the blunt ball tips 14" of electrodes 14 can be configured to be atraumatic and/or less likely to puncture tissue through the use of atraumatic soft/compressible coatings 21 such as silicone or other medical elastomers known in the art, as well as foam polymer material known in the art.

10 5 Coating 21 can be configured to compress to absorb some of the force (including compressive force) applied by tip 14" against the tonsil capsule wall 11" and reduce the likelihood of penetration of the back capsule wall 11" of the tonsil 11. In one embodiment coating 21 is configured to have a compressive modulus 21' less than that of capsule wall of the tonsil. In related embodiments, 15 coating 21 can be configured to be electrically and/or thermally insulative and can be the same as or otherwise integral with insulator 20.

20 Referring now to FIG. 10, in various embodiments cell necrosis apparatus 10 is coupled to an open or closed loop feedback system 25. In one embodiment open or closed loop feedback system 25 couples sensor 346 to 25 energy source 392. In this embodiment, energy delivery device 314 is one or more RF electrodes 314. The temperature of the tissue, or of RF electrode 314 is monitored, and the output power of energy source 392 adjusted accordingly. 30 Additionally, the level of disinfection in the oral cavity can be monitored. The physician can, if desired, override the closed or open loop system. A 20 microprocessor can be included and incorporated in the closed or open loop system to switch power on and off, as well as modulate the power. The closed 35 loop system utilizes a microprocessor 394 to serve as a controller, monitor the temperature, adjust the RF power, analyze the result, refeed the result, and then modulate the power.

40 25 With the use of sensor 346 and the feedback control system a tissue adjacent to RF electrode 314 can be maintained at a desired temperature for a selected period of time without impeding out. Each RF electrode 314 is 45 connected to resources which generate an independent output. The output maintains a selected energy at RF electrode 314 for a selected length of time.

30 30 Current delivered through RF electrode 314 is measured by current sensor 396. Voltage is measured by voltage sensor 398. Impedance and power

5 are then calculated at power and impedance calculation device 400. These values can then be displayed at user interface and display 402. Signals representative of power and impedance values are received by a controller 404.

10 A control signal is generated by controller 404 that is proportional to the
5 difference between an actual measured value, and a desired value. The control signal is used by power circuits 406 to adjust the power output in an appropriate amount in order to maintain the desired power delivered at respective RF electrodes 314.

15 In a similar manner, temperatures detected at sensor 346 provide
10 feedback for maintaining a selected power. Temperature at sensor 346 is used as a safety means to interrupt the delivery of energy when maximum pre-set temperatures are exceeded. The actual temperatures are measured at temperature measurement device 408, and the temperatures are displayed at user interface and display 402. A control signal is generated by controller 404 that is
20 proportional to the difference between an actual measured temperature and a desired temperature. The control signal is used by power circuits 406 to adjust the power output in an appropriate amount in order to maintain the desired temperature delivered at the sensor 346. A multiplexer can be included to measure current, voltage and temperature, at the sensor 346, and energy can be
25 delivered to RF electrode 314 in monopolar or bipolar fashion.

30 Controller 404 can be a digital or analog controller, or a computer with software. When controller 404 is a computer it can include a CPU coupled through a system bus. On this system can be a keyboard, a disk drive, or other non-volatile memory systems, a display, and other peripherals, as are known in
35 the art. Also coupled to the bus is a program memory and a data memory.

40 User interface and display 402 includes operator controls and a display. Controller 404 can be coupled to imaging systems, including but not limited to ultrasound, CT scanners, X-ray, MRI, mammographic X-ray and the like.
45 Further, direct visualization and tactile imaging can be utilized.

30 The output of current sensor 396 and voltage sensor 398 is used by controller 404 to maintain a selected power level at RF electrode 314. The

5 amount of RF energy delivered controls the amount of power. A profile of power delivered can be incorporated in controller 404 and a preset amount of energy to be delivered may also be profiled.

10 Circuitry, software and feedback to controller 404 result in process control, and the maintenance of the selected power setting that is independent of changes in voltage or current, and used to change, (i) the selected power setting, (ii) the duty cycle (on-off time), (iii) bipolar or monopolar energy delivery and 15 (iv) fluid delivery, including flow rate and pressure. These process variables are controlled and varied, while maintaining the desired delivery of power independent of changes in voltage or current, based on temperatures monitored at sensor 346.

20 Referring now to FIG. 11, current sensor 396 and voltage sensor 398 are connected to the input of an analog amplifier 410. Analog amplifier 410 can be a conventional differential amplifier circuit for use with sensor 346. The output 25 of analog amplifier 410 is sequentially connected by an analog multiplexer 412 to the input of A/D converter 414. The output of analog amplifier 410 is a voltage which represents the respective sensed temperatures. Digitized amplifier output voltages are supplied by A/D converter 414 to microprocessor 394. Microprocessor 394 may be a type 68HC11 available from Motorola. 30 However, it will be appreciated that any suitable microprocessor or general purpose digital or analog computer can be used to calculate impedance or temperature.

35 Microprocessor 394 sequentially receives and stores digital representations of impedance and temperature. Each digital value received by 40 microprocessor 394 corresponds to different temperatures and impedances.

45 Calculated power and impedance values can be indicated on user interface and display 402. Alternatively, or in addition to the numerical indication of power or impedance, calculated impedance and power values can be compared by microprocessor 394 with power and impedance limits. When 50 the values exceed predetermined power or impedance values, a warning can be given on user interface and display 402, and additionally, the delivery of RF

5 energy can be reduced, modified or interrupted. A control signal from microprocessor 394 can modify the power level supplied by energy source 392.

FIG. 12 illustrates a block diagram of a temperature/impedance feedback system that can be used to control energy delivery and/or fluid flow rate to
10 electrode 314 and/or a tissue site 416 to regulate the temperature of either or both. Energy is delivered to RF electrode 314 by energy source 392, and applied to tissue site 416. A monitor 420 ascertains tissue impedance, based on
15 the energy delivered to tissue, and compares the measured impedance value to a set value. If the measured impedance exceeds the set value, a disabling signal
20 422 is transmitted to energy source 392, ceasing further delivery of energy to electrode 314. If measured impedance is within acceptable limits, energy continues to be applied to the tissue. During the application of energy, sensor
25 346 measures the temperature of tissue and/or electrode 314. A comparator 424 receives a signal representative of the measured temperature and compares this
30 value to a pre-set signal representative of the desired temperature. Comparator 424 sends a signal to a flow regulator 418 representing a need for a higher temperature control fluid flow rate, if the tissue temperature is too high, or to maintain the flow rate if the temperature has not exceeded the desired temperature.

20 The foregoing description of a preferred embodiment of the invention has been presented for purposes of illustration and description. It is not
35 intended to be exhaustive or to limit the invention to the precise forms disclosed. Obviously, many modifications and variations will be apparent to practitioners skilled in this art. It is intended that the scope of the invention be
40 25 defined by the following claims and their equivalents.

What is claimed is:

Claims

5

10

15

20

25

30

35

40

45

50

55

5

CLAIMS

10

15

1. A cell necrosis apparatus, comprising:
5 an elongated member with a longitudinal axis, the elongated member being configured to be positionable and maneuverable in an oral cavity; and
a first and a second energy delivery device positioned at a distal portion
of the elongated member, the first and second energy delivery devices being
laterally offset from the longitudinal axis.

10

20

2. The apparatus of claim 1, further comprising:
a template coupled to the distal portion of the elongated member.

25

3. The apparatus of claim 2, wherein the template includes a tissue
15 interface surface positionable at an exterior surface of a tonsil.

30

4. The apparatus of claim 3, wherein the first and second energy
delivery devices are coupled to the template.

20

35

5. The apparatus of claim 1, wherein the first energy delivery
device is a first RF electrode and the second energy delivery device is a second
RF electrode.

40

6. The apparatus of claim 5, further comprising:
25 an RF energy source coupled to each of the RF electrodes.

45

7. The apparatus of claim 5, further comprising:
a groundpad electrode electrically coupled to the first and second RF
electrodes.

30

50

55

5 8. The apparatus of claim 5, wherein the first and the second RF
electrodes are configured to operate in a bipolar mode.

10 9. The apparatus of claim 5, wherein the first and the second RF
5 electrodes are configured to operate in a monopolar mode.

15 10. The apparatus of claim 1, further comprising:
a cooling device coupled to the first and the second energy delivery
devices.

20 11. The apparatus of claim 5, further comprising:
a first insulator sleeve positioned at an exterior surface of the first RF
electrode and a second insulator sleeve positioned at an exterior surface of the
second RF electrode.

25 12. The apparatus of claim 5, further comprising:
a sensor coupled to the first RF electrode.

30 13. The apparatus of claim 12, further comprising:
20 a feedback control system coupled to at least one of the sensor or an RF
energy source.

35 14. The apparatus of claim 5, wherein the first RF electrode has a
first energy delivery surface and the second RF electrode has a second energy
40 25 delivery surface.

45 15. The apparatus of claim 14, wherein each of the first and second
RF electrodes has a tissue piercing distal end.

50 16. The apparatus of claim 14, wherein the first energy delivery
surface and the second energy delivery surface each has a size that is sufficient

5 to create cell necrosis in a tonsil intratonsil lymphoid stroma while substantially preserving a tonsil fibrous capsule and a mucosal surface.

10 17. A tonsil treatment apparatus, comprising:
5 a template including a first tissue penetrating introducer with a first lumen; and
a first energy delivery device at least partially positionable in the first
15 lumen, the first energy delivery device being advancable from the first lumen into a tonsil intratonsil lymphoid stroma.

10 18. The apparatus of claim 17, wherein the first energy delivery device has an energy delivery surface, wherein a distal end of the first energy delivery device is configured to deliver substantially no energy.

25 19. The apparatus of claim 17, wherein a distal end of the first energy delivery device is less tissue penetrating than a distal end of the first tissue penetrating introducer.

30 20. The apparatus of claim 17, wherein a distal end of a first energy delivery device is substantially blunt.

35 21. The apparatus of claim 19, wherein the distal end of the first energy delivery device has one of a spherical shape, a cylindrical shape, a substantially convex surface shape, or a substantially concave surface shape.

40 22. The apparatus of claim 19, wherein the distal end of the first of energy delivery device has an atraumatic coating.

45 23. The apparatus of claim 22, wherein the atraumatic coating is an
30 elastomer, a foam polymer or a silicone.

- 5 24. The apparatus of claim 22, wherein the atraumatic coating is configured to have a compressive modulus less than that of a back capsule wall of a tonsil.
- 10 5 25. The apparatus of claim 19, wherein the distal end of the first energy delivery device is coupled to a force sensor.
- 15 26. The apparatus of claim 17, wherein the first energy delivery device has an elongated section and a distal end.
- 10 27. The apparatus of claim 26, wherein the distal end of the first energy delivery device has a larger cross-sectional diameter than the elongated section of the first energy delivery device.
- 20 28. The apparatus of claim 17, further comprising:
an elongated member coupled to the template.
- 25 29. The apparatus of claim 17, wherein the template has a tissue interface surface that is substantially non-conductive of electromagnetic energy.
- 30 30. The apparatus of claim 17, wherein the first energy delivery device is an RF electrode.
- 35 31. The apparatus of claim 17, further comprising:
the template including a second tissue penetrating introducer with a second lumen; and
a second energy delivery device at least partially positionable in the second lumen, the second energy delivery device being advancable from the second lumen into the tonsil intratonsil lymphoid stroma.
- 40 45 30

5 32. The apparatus of claim 31, wherein the second energy delivery device has an energy delivery surface, wherein a distal end of the second energy delivery device includes an electromagnetically non-conductive surface.

10 5 33. The apparatus of claim 31, wherein a distal end of the second energy delivery device is less tissue penetrating than a distal end of the second tissue penetrating introducer.

15 34. The apparatus of claim 31, wherein a distal end of the second energy delivery device is substantially blunt.

20 35. The apparatus of claim 33, wherein the distal end of the second energy delivery device has one of a spherical shape, a cylindrical shape, a substantially convex surface shape, or a substantially concave surface shape.

25 15 36. The apparatus of claim 33, wherein the distal end of the second energy delivery device has an atraumatic coating.

30 37. The apparatus of claim 36, wherein the atraumatic coating is an elastomer, a foam polymer or a silicone.

35 38. The apparatus of claim 36, wherein the atraumatic coating is configured to have a compressive modulus less than that of a back capsule wall of a tonsil.

40 25 39. The apparatus of claim 33, wherein the distal end of the second electrode is coupled to a force sensor.

45 40. The apparatus of claim 31, wherein the second energy delivery device has an elongated section and a distal end.

50

55

- 5 41. The apparatus of claim 40, wherein the distal end of the second
energy delivery device has a larger cross-sectional diameter than an elongated
section of the first energy delivery device.
- 10 5 42. The apparatus of claim 40, wherein the first energy delivery
surface and the second energy delivery surface each have a size that is sufficient
to create cell necrosis in the tonsil intratonsil lymphoid stroma while preserving
15 a tonsil fibrous capsule and mucosal surface.
- 10 43. A cell necrosis apparatus, comprising:
an elongated member with a longitudinal axis, the elongated member
20 being configured to be positionable and maneuverable in an oral cavity;
a template positioned at a distal portion of the elongated member;
a tissue piercing stylet coupled to the template; and
25 15 an energy delivery member positionable in the stylet.
- 30 44. The apparatus of claim 43, wherein a distal end of the energy
delivery member has a blunt tip.
- 20 45. The apparatus of claim 43, wherein a distal end of the energy
delivery member is substantially electromagnetically non-conductive.
- 35 46. The apparatus of claim 43, wherein the template includes a tissue
interface surface positionable at an exterior surface of a tonsil.
- 40 25 47. The apparatus of claim 43, wherein the energy delivery device is
an RF electrode.
- 45 48. The apparatus of claim 47, further comprising:
30 a groundpad electrode electrically coupled to the RF electrode.

- 5 49. The apparatus of claim 47, further comprising:
an insulator sleeve positioned at an exterior surface of the RF electrode.
- 10 50. The apparatus of claim 47, further comprising:
5 a sensor coupled to the RF electrode.
- 15 51. The apparatus of claim 50, further comprising:
a feedback control system coupled to the sensor.
- 20 52. A method of reducing a size of a tonsil, comprising:
providing an elongated member coupled to a first energy delivery device
with an energy delivery surface;
introducing at least a portion of the energy delivery surface into an
interior of the tonsil;
25 15 creating cell necrosis in a tonsil intratonsil lymphoid stroma while
substantially preserving a tonsil fibrous capsule.
- 30 53. The method of claim 52, wherein cell necrosis is created in the
tonsil intratonsil lymphoid stroma while substantially preserving a tonsil
20 mucosal surface.
- 35 54. The method of claim 52, further comprising:
ablating a portion of the tonsil intratonsil lymphoid stroma.
- 40 55. The method of claim 52, further comprising:
25 reducing a volume of the tonsil.
- 45 56. The method of claim 52, further comprising:
receiving feedback on a force applied by the surface of the first energy
30 delivery device to the tonsil fibrous capsule.

- 5 57. A cell necrosis apparatus, comprising:
an elongated member with a longitudinal axis, the elongated member
being configured to be positionable and maneuverable in an oral cavity; and
10 an energy delivery device positioned at a distal portion of the elongated
5 member and being laterally offset from the longitudinal axis, the energy
delivery device having a substantially blunt tip.
- 15 58. The apparatus of claim 57, wherein the substantially blunt tip is
configured to be advanceable through tissue with a minimum of tissue tearing.
- 10 59. The apparatus of claim 57, wherein the tissue is muscle tissue,
adipose tissue, tonsil intratonsil lymphoid stroma or tonsil fibrous capsule.
- 20 60. The apparatus of claim 57, wherein the substantially blunt tip is
25 configured to impede penetration of one of a tonsil fibrous capsule or a blood
vessel.
- 30 61. A method of reducing a size of a pharyngeal structure,
comprising:
20 providing an elongated member coupled to a first energy delivery device
with an energy delivery surface;
35 introducing at least a portion of the energy delivery surface into an
interior of one of a pharyngeal fat pad or a pterygoid fat pad;
creating cell necrosis in one of the pharyngeal fat pad or the pterygoid
40 25 fat pad while minimizing injury to substantially adjacent tissue including
muscle, vasculature or nerve.
- 45 62. The method of claim 61, wherein the muscle is a pterygoid muscle.
- 30 63. The method of claim 61, wherein the vasculature is a pterygoid artery, a
50 pterygoid plexus, or a deep facial vein.

5

64. The method of claim 61, wherein the nerve is a nerve of the pterygoid canal.

10

5 65. The method of claim 61, further comprising:
ablating a portion of one of the pharyngeal fat pad or the pterygoid fat pad.

15

66. The method of claim 61, further comprising:
10 reducing a volume of one of the pharyngeal fat pad or the pterygoid fat pad.

20

25

30


35

40

45

50

55






FIG. 2A

3/12




FIG. 2B

SUBSTITUTE SHEET (RULE 26)




FIG. 3

5/12




FIG. 4




FIG. 5




FIG. 6




FIG. 7

6/12




FIG. 8A




FIG. 8B





FIG. 9A






FIG. 9C




FIG. 10




FIG. 11




FIG. 12

INTERNATIONAL SEARCH REPORT

Internati Application No
PCT/Us 00/16800

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61B18/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 718 702 A (EDWARDS STUART D) 17 February 1998 (1998-02-17)	1-17, 26, 30, 31, 43, 46-51
A	the whole document	57
Y	US 5 743 904 A (EDWARDS STUART D) 28 April 1998 (1998-04-28)	1-17, 26, 30, 31, 43, 46-51
A	column 2, line 39-44 US 5 707 349 A (EDWARDS STUART D) 13 January 1998 (1998-01-13) the whole document	1-51, 57-66
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"8" document member of the same patent family

Date of the actual completion of the international search

25 October 2000

Date of mailing of the international search report

31/10/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Papone, F

1

INTERNATIONAL SEARCH REPORT

Internat' Application No
PCT/US 00/16800

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 836 906 A (EDWARDS STUART D) 17 November 1998 (1998-11-17) column 6, line 5-15 column 7, line 39-54 ----	1-51, 57-66
A	WO 99 07299 A (LAX RONALD G ;EDWARDS STUART D (US); SOMNUS MEDICAL TECHNOLOGIES I) 18 February 1999 (1999-02-18) -----	

INTERNATIONAL SEARCH REPORT

Internet Application No
PCT/US 00/16800

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5718702 A	17-02-1998	US 5514131 A	07-05-1996
		US 5370675 A	06-12-1994
		US 5435805 A	25-07-1995
		US 5421819 A	06-06-1995
		US 5385544 A	31-01-1995
		US 5456662 A	10-10-1995
		AU 2070897 A	26-11-1997
		AU 3119597 A	26-11-1997
		CA 2253705 A	13-11-1997
		CN 1217639 A	26-05-1999
		EP 0904025 A	31-03-1999
		JP 2000509619 T	02-08-2000
		WO 9741786 A	13-11-1997
		WO 9741789 A	13-11-1997
		US 5743904 A	28-04-1998
		US 6077257 A	20-06-2000
		AT 132046 T	15-01-1996
		AU 671405 B	22-08-1996
		AU 2047595 A	10-08-1995
		AU 657235 B	02-03-1995
		AU 4999893 A	15-03-1994
		BR 9306893 A	08-12-1998
		CA 2121032 A,C	03-03-1994
		CA 2226484 A	03-03-1994
		DE 4305663 A	17-02-1994
		DE 69301143 D	08-02-1996
		DE 69325164 D	08-07-1999
		DE 69325164 T	25-05-2000
		EP 0611314 A	24-08-1994
		EP 0629382 A	21-12-1994
		EP 0893101 A	27-01-1999
		ES 2084510 T	01-05-1996
		ES 2134295 T	01-10-1999
		FI 950584 A	04-04-1995
		FR 2694700 A	18-02-1994
		GB 2269538 A,B	16-02-1994
		IL 104647 A	31-12-1995
		JP 7503645 T	20-04-1995
		MX 9304905 A	29-04-1994
		NZ 255687 A	20-12-1996
		US 6022334 A	08-02-2000
		US 6102886 A	15-08-2000
		WO 9404220 A	03-03-1994
		US 5409453 A	25-04-1995
		US 5470308 A	28-11-1995
		US 5366490 A	22-11-1994
		US 5556377 A	17-09-1996
		US 5720718 A	24-02-1998
		US 5542915 A	06-08-1996
		US 5470309 A	28-11-1995
US 5743904 A	28-04-1998	US 5836906 A	17-11-1998
		US 5738114 A	14-04-1998
		US 5718702 A	17-02-1998
		US 5743870 A	28-04-1998
		AU 3119597 A	26-11-1997
		WO 9741789 A	13-11-1997
		US 6077257 A	20-06-2000

Form PCT/ISA(2)C (patent family annex) (July 1992)

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/US 00/16800

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5743904 A		AU 2278297 A	10-09-1997
		AU 3077497 A	09-12-1997
		AU 3141397 A	09-12-1997
		AU 3145597 A	09-12-1997
		AU 6850696 A	09-12-1997
		CA 2253847 A	27-11-1997
		CN 1219885 A	16-06-1999
		EP 0959785 A	01-12-1999
		EP 0901398 A	17-03-1999
		WO 9743969 A	27-11-1997
		WO 9730646 A	28-08-1997
		WO 9744092 A	27-11-1997
		WO 9743972 A	27-11-1997
		WO 9743973 A	27-11-1997
		US 5800379 A	01-09-1998
		US 5879349 A	09-03-1999
		US 5730719 A	24-03-1998
		US 5820580 A	13-10-1998
		US 6126657 A	03-10-2000
		AU 1968697 A	10-09-1997
		WO 9730645 A	28-08-1997
		AU 2070897 A	26-11-1997
		CA 2253705 A	13-11-1997
		CN 1217639 A	26-05-1999
		EP 0904025 A	31-03-1999
		JP 2000509619 T	02-08-2000
		WO 9741786 A	13-11-1997
		AU 1989597 A	26-11-1997
		WO 9741787 A	13-11-1997
		AU 2191697 A	09-12-1997
		AU 3204097 A	09-12-1997
		WO 9743970 A	27-11-1997
		WO 9743971 A	27-11-1997
		US 5800429 A	01-09-1998
		US 5746224 A	05-05-1998
		US 5827277 A	27-10-1998
		US 5823197 A	20-10-1998
		US 5843077 A	01-12-1998
US 5707349 A	13-01-1998	US 5674191 A	07-10-1997
		US 5456662 A	10-10-1995
		AU 1968697 A	10-09-1997
		AU 2135597 A	10-09-1997
		AU 2278297 A	10-09-1997
		AU 718288 B	13-04-2000
		AU 6898896 A	10-09-1997
		EP 0957796 A	24-11-1999
		WO 9730644 A	28-08-1997
		WO 9730645 A	28-08-1997
		WO 9730646 A	28-08-1997
		WO 9730647 A	28-08-1997
		US 5728094 A	17-03-1998
		US 5807308 A	15-09-1998
		US 5738114 A	14-04-1998
		US 5836906 A	17-11-1998
		US 5800379 A	01-09-1998
		US 5879349 A	09-03-1999
		US 5730719 A	24-03-1998

Form PCT/SA/210 (patent family annex) (July 1992)

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/US 00/16800

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5707349 A		US 5820580 A	13-10-1998
		US 5817049 A	06-10-1998
		US 6126657 A	03-10-2000
		US 5843021 A	01-12-1998
		AU 7007896 A	12-03-1997
		NL 1003812 C	02-07-1997
		NL 1003812 A	20-02-1997
		WO 9706738 A	27-02-1997
		US 5743870 A	28-04-1998
		US 5514131 A	07-05-1996
		US 5718702 A	17-02-1998
US 5836906 A	17-11-1998	US 5728094 A	17-03-1998
		US 5707349 A	13-01-1998
		AU 2278297 A	10-09-1997
		AU 3077497 A	09-12-1997
		AU 3119597 A	26-11-1997
		AU 3141397 A	09-12-1997
		AU 3145597 A	09-12-1997
		AU 6850696 A	09-12-1997
		CA 2253847 A	27-11-1997
		CN 1219885 A	16-06-1999
		EP 0959785 A	01-12-1999
		EP 0901398 A	17-03-1999
		WO 9743969 A	27-11-1997
		WO 9730646 A	28-08-1997
		WO 9741789 A	13-11-1997
		WO 9744092 A	27-11-1997
		WO 9743972 A	27-11-1997
		WO 9743973 A	27-11-1997
		US 5743904 A	28-04-1998
		US 5800379 A	01-09-1998
		US 5879349 A	09-03-1999
		US 5730719 A	24-03-1998
		US 6077257 A	20-06-2000
		US 5820580 A	13-10-1998
		US 6126657 A	03-10-2000
		AU 1968697 A	10-09-1997
		AU 2135597 A	10-09-1997
		AU 702374 B	18-02-1999
		AU 6851496 A	12-03-1997
		EP 0850023 A	01-07-1998
		JP 11511054 T	28-09-1999
		WO 9706741 A	27-02-1997
		WO 9730645 A	28-08-1997
		WO 9730647 A	28-08-1997
		US 5738114 A	14-04-1998
		AU 718288 B	13-04-2000
		AU 6898896 A	10-09-1997
		EP 0957796 A	24-11-1999
		WO 9730644 A	28-08-1997
		US 5807308 A	15-09-1998
		US 5817049 A	06-10-1998
		US 5843021 A	01-12-1998
WO 9907299 A	18-02-1999	US 5843021 A	01-12-1998
		AU 7809998 A	01-03-1999
		EP 1001710 A	24-05-2000

Form PCT/ISA/210 (patent family annex) (July 1992)